<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Pharm Pract</journal-id><journal-id journal-id-type="iso-abbrev">J Res Pharm Pract</journal-id><journal-id journal-id-type="publisher-id">JRPP</journal-id><journal-title-group><journal-title>Journal of Research in Pharmacy Practice</journal-title></journal-title-group><issn pub-type="ppub">2319-9644</issn><issn pub-type="epub">2279-042X</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26985431</article-id><article-id pub-id-type="pmc">4776542</article-id><article-id pub-id-type="publisher-id">JRPP-5-16</article-id><article-id pub-id-type="doi">10.4103/2279-042X.176556</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prophylactic antiemetic effects of Midazolam, Ondansetron, and their combination after middle ear surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Honarmand</surname><given-names>Azim</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Safavi</surname><given-names>Mohammadreza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Chegeni</surname><given-names>Mansoureh</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hirmanpour</surname><given-names>Anahita</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nazem</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sarizdi</surname><given-names>Seyyad Hamid</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>2</label>Department of Peadiatric Surgery, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Prof. Mohammadreza Safavi, E-mail: <email xlink:href="safavi@med.mui.ac.ir">safavi@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2016</year></pub-date><volume>5</volume><issue>1</issue><fpage>16</fpage><lpage>21</lpage><history><date date-type="received"><month>8</month><year>2015</year></date><date date-type="accepted"><month>9</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: © Journal of Research in Pharmacy Practice</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3667" xml_f="3677" txt_i="11" txt_f="21">Objective:</offsets></title><p><offsets xml_i="3688" xml_f="3931" txt_i="22" txt_f="265">The purpose of the present study was to evaluate the efficacy of midazolam-ondansetron combination in prevention of postoperative nausea and vomiting (PONV) after middle ear surgery and its comparison with using midazolam or ondansetron alone.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3962" xml_f="3970" txt_i="267" txt_f="275">Methods:</offsets></title><p><offsets xml_i="3981" xml_f="4390" txt_i="276" txt_f="685">One hundred and forty patients were enrolled in four groups to receive midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, midazolam 0.75 mg/kg and ondansetron 4 mg in group MO, and saline 0.90% in group S intravenously just before anesthesia. Assessment of nausea, vomiting, rescue antiemetic, and side effects of study drugs such as headache and dizziness was carried out postoperatively for 24 h.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4421" xml_f="4430" txt_i="687" txt_f="696">Findings:</offsets></title><p><offsets xml_i="4441" xml_f="4822" txt_i="697" txt_f="1078">The incidence of PONV was significantly smaller in group MO than group M and group O, while there was no significant difference between group M and group O during the first 24 h postoperatively. Requirement to the additional antiemetic was significantly more in group S (71.4%) compared to other groups, while in group MO (11.4%) was lower than group M (31.4%) and group O (34.3%).</offsets></p></sec><sec id="st4"><title><offsets xml_i="4853" xml_f="4864" txt_i="1080" txt_f="1091">Conclusion:</offsets></title><p><offsets xml_i="4875" xml_f="5088" txt_i="1092" txt_f="1305">Our study showed that prophylactic administration of midazolam 0.75 mg/kg combined with ondansetron 4 mg was more effective than using midazolam or ondansetron alone in prevention of PONV after middle ear surgery.</offsets></p></sec></abstract><kwd-group><kwd>Midazolam</kwd><kwd>middle ear surgery</kwd><kwd>Ondansetron</kwd><kwd>postoperative nausea and vomiting</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5317" xml_f="5329" txt_i="1314" txt_f="1326">INTRODUCTION</offsets></title><p><offsets xml_i="5340" xml_f="5484" txt_i="1327" txt_f="1471">Postoperative nausea and vomiting (PONV) are common and distressing complications and are the main concern of 40–70% of patients after surgery.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5517" xml_f="5518" txt_i="1471" txt_f="1472">1</offsets></xref><xref rid="ref2" ref-type="bibr"><offsets xml_i="5558" xml_f="5559" txt_i="1472" txt_f="1473">2</offsets></xref><offsets xml_i="5566" xml_f="5809" txt_i="1473" txt_f="1716">] PONV dose not only cause patient discomfort but also can lead to prolongation of stay in the postanesthesia care unit (PACU) and to serious complications including electrolyte imbalance, aspiration, increased bleeding, and wound dehiscence.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="5842" xml_f="5843" txt_i="1716" txt_f="1717">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="5883" xml_f="5884" txt_i="1717" txt_f="1718">4</offsets></xref><offsets xml_i="5891" xml_f="5995" txt_i="1718" txt_f="1822">] Patients who suffer from PONV require additional healthcare professional time and material resources.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6028" xml_f="6029" txt_i="1822" txt_f="1823">3</offsets></xref><offsets xml_i="6036" xml_f="6164" txt_i="1823" txt_f="1951">] The incidence of PONV is approximately 25–30% in general surgery population and between 62% and 80% after middle ear surgery.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="6197" xml_f="6198" txt_i="1951" txt_f="1952">5</offsets></xref><offsets xml_i="6205" xml_f="6402" txt_i="1952" txt_f="2149">] Many factors such as the site and characteristics of the surgical procedure, the anesthetic technique, as well as the age, gender, weight of the patients, and vertigo history may influence PONV.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="6435" xml_f="6436" txt_i="2149" txt_f="2150">6</offsets></xref><xref rid="ref7" ref-type="bibr"><offsets xml_i="6476" xml_f="6477" txt_i="2150" txt_f="2151">7</offsets></xref><offsets xml_i="6484" xml_f="6582" txt_i="2151" txt_f="2249">] The timing and the dose of the antiemetic agent to be used in the treatment are also important.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="6615" xml_f="6616" txt_i="2249" txt_f="2250">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="6656" xml_f="6657" txt_i="2250" txt_f="2251">9</offsets></xref><xref rid="ref10" ref-type="bibr"><offsets xml_i="6698" xml_f="6700" txt_i="2251" txt_f="2253">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="6741" xml_f="6743" txt_i="2253" txt_f="2255">11</offsets></xref><xref rid="ref12" ref-type="bibr"><offsets xml_i="6784" xml_f="6786" txt_i="2255" txt_f="2257">12</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="6827" xml_f="6829" txt_i="2257" txt_f="2259">13</offsets></xref><xref rid="ref14" ref-type="bibr"><offsets xml_i="6870" xml_f="6872" txt_i="2259" txt_f="2261">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="6913" xml_f="6915" txt_i="2261" txt_f="2263">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="6956" xml_f="6958" txt_i="2263" txt_f="2265">16</offsets></xref><offsets xml_i="6965" xml_f="6966" txt_i="2265" txt_f="2266">]</offsets></p><p><offsets xml_i="6973" xml_f="7135" txt_i="2267" txt_f="2429">Ondansetron is a 5-hydroxytryptamine 3 (5-HT3) antagonist which usually recommended for prevention and treatment of nausea and vomiting during and after surgery.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="7169" xml_f="7171" txt_i="2429" txt_f="2431">17</offsets></xref><offsets xml_i="7178" xml_f="7522" txt_i="2431" txt_f="2775">] It works by blocking the action of serotonin, a natural substance, that may cause nausea and vomiting. Midazolam is in a class of medications called benzodiazepines. It has antiemetic effect by augmentation of the inhibitory effects of gamma amino butyric acid and adenosine-mediated inhibition of dopamine in the chemoreceptor trigger zone.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="7556" xml_f="7558" txt_i="2775" txt_f="2777">12</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="7599" xml_f="7601" txt_i="2777" txt_f="2779">18</offsets></xref><offsets xml_i="7608" xml_f="7609" txt_i="2779" txt_f="2780">]</offsets></p><p><offsets xml_i="7616" xml_f="7704" txt_i="2781" txt_f="2869">The efficacy of ondansetron or midazolam in prevention of PONV was investigated before.[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="7738" xml_f="7740" txt_i="2869" txt_f="2871">18</offsets></xref><offsets xml_i="7747" xml_f="7837" txt_i="2871" txt_f="2961">] In a previous study, the incidence of PONV after using midazolam or ondansetron was 45%[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="7871" xml_f="7873" txt_i="2961" txt_f="2963">18</offsets></xref><offsets xml_i="7880" xml_f="7891" txt_i="2963" txt_f="2974">] and 22%,[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7924" xml_f="7925" txt_i="2974" txt_f="2975">5</offsets></xref><offsets xml_i="7932" xml_f="8402" txt_i="2975" txt_f="3445">] respectively. Our hypothesis was that using the combination of midazolam with ondansetron probably reduces the incidence of PONV after middle ear surgery better than using each drug singly. There was not previous study about antiemetic effect of midazolam-ondansetron combination, so we design the present study to evaluate the effect of midazolam, ondansetron, and their combination in prevention of PONV after middle ear surgery in comparison with the placebo group.</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="8455" xml_f="8462" txt_i="3447" txt_f="3454">METHODS</offsets></title><p><offsets xml_i="8473" xml_f="9094" txt_i="3455" txt_f="4076">After obtaining institutional approval from Ethic Committee of university and informed consent from patients, 140 American Society of Anesthesiologist I or II patients, aged 18–62 years who were eligible to participate in this double-blinded randomized clinical trial. These patients were scheduled for elective middle ear surgery, mastoidectomy, or tympanoplasty. Patients with previous history of motion sickness, antiemetic therapy within 24h preoperatively, patients on opioid treatment, smokers, and pregnant patients were not included. If anesthetic technique was changed, the patients were excluded from the study.</offsets></p><p><offsets xml_i="9101" xml_f="9508" txt_i="4077" txt_f="4484">Patients were randomized into four groups receiving midazolam 0.75 mg/kg (group M), ondansetron 4 mg (group O), combination of midazolam 0.75 mg/kg and ondansetron 4 mg (group MO), and saline 0.9% (group S) intravenously (IV) before induction of anesthesia. The randomization was done by using random allocation software. The study drugs were administered by an anesthesiologist blinded to data collection.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="9542" xml_f="9544" txt_i="4484" txt_f="4486">17</offsets></xref><offsets xml_i="9551" xml_f="9552" txt_i="4486" txt_f="4487">]</offsets></p><p><offsets xml_i="9559" xml_f="10176" txt_i="4488" txt_f="5105">Before induction of anesthesia, the patients were informed on the using the visual analog scale (VAS) for nausea and pain evaluation. The monitoring was performed by continuous electrocardiogram, noninvasive blood pressure, pulse oximetry, and end-tidal carbon dioxide. Induction of anesthesia was done with sodium thiopental 5 mg/kg, fentanyl 2 µg/kg, and atracurium 0.6 mg/kg. General anesthesia was maintained with 100–150 µg/kg/min propofol infusion and morphine 0.1 mg/kg for analgesia. Neuromuscular blockage was reversed with neostigmine 0.4 mg/kg and atropine 0.2 mg/kg and after that patients were extubated.</offsets></p><p><offsets xml_i="10183" xml_f="10252" txt_i="5106" txt_f="5175">PONV were evaluated using nausea-vomiting score at 0–2 h and 2–24 h [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="10284" xml_f="10291" txt_i="5175" txt_f="5182">Table 1</offsets></xref><offsets xml_i="10298" xml_f="10388" txt_i="5182" txt_f="5272">]. Vomiting was defined as forceful expulsion of gastric contents from mouth or retching.[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="10422" xml_f="10424" txt_i="5272" txt_f="5274">19</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="10465" xml_f="10467" txt_i="5274" txt_f="5276">20</offsets></xref><offsets xml_i="10474" xml_f="10890" txt_i="5276" txt_f="5692">] Postoperative nausea and pain intensity were evaluated by using VAS at 0–2 and 2–24 h with 0 = no pain or PONV and 10 = the worst imaginable pain or PONV. Patients with a PONV score of 2 or more were given IV metoclopramide 0.15 mg/kg, and that dose was recorded. Time to the first oral intake was recorded. Patients with a pain score of 4 or more were given diclofenac suppository 50 mg and its dose was recorded.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="10938" xml_f="10945" txt_i="5693" txt_f="5700">Table 1</offsets></label><caption><p><offsets xml_i="10965" xml_f="10990" txt_i="5700" txt_f="5725">Nausea and vomiting score</offsets></p></caption><graphic xlink:href="JRPP-5-16-g001"></graphic></table-wrap><p><offsets xml_i="11067" xml_f="11274" txt_i="5726" txt_f="5933">Length of staying in the recovery room was evaluated by using Modified Aldrete Score. Extubation time (defined since discontinuation of anesthetic drugs until removal of endotracheal tube) was also recorded.</offsets></p><p><offsets xml_i="11281" xml_f="11438" txt_i="5934" txt_f="6091">The patient's satisfaction was rated on a 10-point scale from 0 to 10 where 0 represented “no satisfaction at all and 10 represented complete satisfaction.”[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="11472" xml_f="11474" txt_i="6091" txt_f="6093">19</offsets></xref><offsets xml_i="11481" xml_f="11576" txt_i="6093" txt_f="6188">] Complete response was defined as absence of nausea and vomiting during 24 h postoperatively.[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="11610" xml_f="11612" txt_i="6188" txt_f="6190">19</offsets></xref><offsets xml_i="11619" xml_f="11800" txt_i="6190" txt_f="6371">] Consciousness was assessed based on Observer's Assessment of Alertness/Sedation scale at the time of evaluation of nausea and vomiting (where 1 = awake/alert, and 5 = deep sleep).</offsets></p><p><offsets xml_i="11807" xml_f="12238" txt_i="6372" txt_f="6803">The sample size was estimated based on a power calculation which showed that 35 patients per group were necessary to achieve 80% power to detect a 30% difference (from 50% to 20%) in the incidence of PONV between group O with group MO with α =0.05 The data was presented as mean ± standard deviation or numbers (%). Differences among groups for quantitative variables was analyzed by using one-way analysis of variance (ANOVA) and </offsets><italic><offsets xml_i="12246" xml_f="12254" txt_i="6803" txt_f="6811">post hoc</offsets></italic><offsets xml_i="12263" xml_f="12596" txt_i="6811" txt_f="7144"> comparisons at various points in time by using Bonferroni's type I error rate correction for multiple tests of significance. Analysis of continuous variables was done by using repeated measure ANOVA. Categorical variables were analyzed by using Chi-square test. Mann–Whitney U-test and Kruskal–Wallis test were used as appropriate. </offsets><italic><offsets xml_i="12604" xml_f="12605" txt_i="7144" txt_f="7145">P</offsets></italic><offsets xml_i="12614" xml_f="12771" txt_i="7145" txt_f="7299"> &lt;0.05 was considered statistically significant. The analysis of data was performed by using SPSS 20.0 software for Windows (SPSS Inc., Chicago, IL, USA).</offsets></p></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="12824" xml_f="12831" txt_i="7301" txt_f="7308">RESULTS</offsets></title><p><offsets xml_i="12842" xml_f="13113" txt_i="7309" txt_f="7580">One hundred forty patients were randomly allocated into four groups, and no patient was excluded. Patient characteristics, operation type, duration of surgery, duration of anesthesia, time to oral intake, extubation time, PACU time, and patient satisfaction are shown in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13145" xml_f="13152" txt_i="7580" txt_f="7587">Table 2</offsets></xref><offsets xml_i="13159" xml_f="13218" txt_i="7587" txt_f="7646">. Time to oral intake was significantly higher in group S (</offsets><italic><offsets xml_i="13226" xml_f="13227" txt_i="7646" txt_f="7647">P</offsets></italic><offsets xml_i="13236" xml_f="13342" txt_i="7647" txt_f="7750"> &lt; 0.001) than to the other groups. PACU time was not significantly different between the four groups [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="13374" xml_f="13381" txt_i="7750" txt_f="7757">Table 2</offsets></xref><offsets xml_i="13388" xml_f="13654" txt_i="7757" txt_f="8023">]. Postoperatively, 11 patients (31.4%) in group M, 12 patients (34.2%) in group O, 4 patients (11.4%) in group MO, and 25 patients (71.4%) in group S, received 0.15 mg/kg metoclopramide IV and there was significant difference between group MO and the other groups (</offsets><italic><offsets xml_i="13662" xml_f="13663" txt_i="8023" txt_f="8024">P</offsets></italic><offsets xml_i="13672" xml_f="13821" txt_i="8024" txt_f="8170"> &lt; 0.001). PONV was significantly less in those patients who received a combination of midazolam and ondansetron as compared to the other groups [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="13853" xml_f="13860" txt_i="8170" txt_f="8177">Table 3</offsets></xref><offsets xml_i="13867" xml_f="14026" txt_i="8177" txt_f="8336">]. Subsequently, the difference was not significant between group M and group O. However, PONV in both of them were significantly less as compared to group S [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="14058" xml_f="14065" txt_i="8336" txt_f="8343">Table 3</offsets></xref><offsets xml_i="14072" xml_f="14258" txt_i="8343" txt_f="8529">]. There was no significant difference between group M with group O in this respect. The overall patient satisfaction was significantly higher in the group MO compared the other groups [</offsets><italic><offsets xml_i="14266" xml_f="14267" txt_i="8529" txt_f="8530">P</offsets></italic><offsets xml_i="14276" xml_f="14289" txt_i="8530" txt_f="8540"> &lt; 0.001, </offsets><xref ref-type="table" rid="T2"><offsets xml_i="14321" xml_f="14328" txt_i="8540" txt_f="8547">Table 2</offsets></xref><offsets xml_i="14335" xml_f="14337" txt_i="8547" txt_f="8549">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="14385" xml_f="14392" txt_i="8550" txt_f="8557">Table 2</offsets></label><caption><p><offsets xml_i="14412" xml_f="14474" txt_i="8557" txt_f="8619">Demographic characteristics and para-clinical data of patients</offsets></p></caption><graphic xlink:href="JRPP-5-16-g002"></graphic></table-wrap><table-wrap id="T3" position="float"><label><offsets xml_i="14592" xml_f="14599" txt_i="8620" txt_f="8627">Table 3</offsets></label><caption><p><offsets xml_i="14619" xml_f="14711" txt_i="8627" txt_f="8719">The incidence of patients with PON, POV, PONV and requiring rescue antiemetic in four groups</offsets></p></caption><graphic xlink:href="JRPP-5-16-g003"></graphic></table-wrap><p><offsets xml_i="14788" xml_f="14856" txt_i="8720" txt_f="8788">VAS of nausea in group MO was significantly less than other groups (</offsets><italic><offsets xml_i="14864" xml_f="14865" txt_i="8788" txt_f="8789">P</offsets></italic><offsets xml_i="14874" xml_f="14960" txt_i="8789" txt_f="8872"> &lt; 0.001). There was no significant difference between VAS of pain in four groups [</offsets><xref ref-type="table" rid="T4"><offsets xml_i="14992" xml_f="14999" txt_i="8872" txt_f="8879">Table 4</offsets></xref><offsets xml_i="15006" xml_f="15117" txt_i="8879" txt_f="8990">]. No significant difference was found between groups in terms of side effects such as dizziness and headache [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="15149" xml_f="15156" txt_i="8990" txt_f="8997">Table 5</offsets></xref><offsets xml_i="15163" xml_f="15165" txt_i="8997" txt_f="8999">].</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="15213" xml_f="15220" txt_i="9000" txt_f="9007">Table 4</offsets></label><caption><p><offsets xml_i="15240" xml_f="15296" txt_i="9007" txt_f="9063">Severity of postoperative nausea and pain in four groups</offsets></p></caption><graphic xlink:href="JRPP-5-16-g004"></graphic></table-wrap><table-wrap id="T5" position="float"><label><offsets xml_i="15414" xml_f="15421" txt_i="9064" txt_f="9071">Table 5</offsets></label><caption><p><offsets xml_i="15441" xml_f="15502" txt_i="9071" txt_f="9132">The incidence of postoperative adverse effects in four groups</offsets></p></caption><graphic xlink:href="JRPP-5-16-g005"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="15628" xml_f="15638" txt_i="9134" txt_f="9144">DISCUSSION</offsets></title><p><offsets xml_i="15649" xml_f="16170" txt_i="9145" txt_f="9666">In the present study, we aimed to compare the antiemetic effect of the combination of midazolam-ondansetron with midazolam and ondansetron single and placebo group. We evaluated the incidence of nausea and vomiting and their severity in the first 24 h and the number of patients with nausea and vomiting who used additional antiemetic between 0–2 and 2–24 h. We measured postoperative pain based on VAS which could effect on the incidence of PONV, and there was no significant difference in pain intensity between groups.</offsets></p><p><offsets xml_i="16177" xml_f="16458" txt_i="9667" txt_f="9948">In this study, we found the incidence of PONV was significantly smaller in group MO than group M and group O and there was no significant difference between group M and group O. Need to the additional antiemetic was significantly lower in group MO compared with group M or group O.</offsets></p><p><offsets xml_i="16465" xml_f="16572" txt_i="9949" txt_f="10056">The use of 5-HT3 receptor antagonists is popular as the drugs have shown good efficacy in preventing PONV.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="16605" xml_f="16606" txt_i="10056" txt_f="10057">3</offsets></xref><xref rid="ref21" ref-type="bibr"><offsets xml_i="16647" xml_f="16649" txt_i="10057" txt_f="10059">21</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="16690" xml_f="16692" txt_i="10059" txt_f="10061">22</offsets></xref><xref rid="ref23" ref-type="bibr"><offsets xml_i="16733" xml_f="16735" txt_i="10061" txt_f="10063">23</offsets></xref><xref rid="ref24" ref-type="bibr"><offsets xml_i="16776" xml_f="16778" txt_i="10063" txt_f="10065">24</offsets></xref><xref rid="ref25" ref-type="bibr"><offsets xml_i="16819" xml_f="16821" txt_i="10065" txt_f="10067">25</offsets></xref><xref rid="ref26" ref-type="bibr"><offsets xml_i="16862" xml_f="16864" txt_i="10067" txt_f="10069">26</offsets></xref><offsets xml_i="16871" xml_f="17139" txt_i="10069" txt_f="10337">] These drugs act by two mechanisms: First, by blocking the 5-HT3 receptors in the area postrema and nucleus tractus solitarius; and second, by blocking peripherally afferent vagal impulses originating from 5-HT3 receptors in the mucosa of the gastrointestinal tract.[</offsets><xref rid="ref27" ref-type="bibr"><offsets xml_i="17173" xml_f="17175" txt_i="10337" txt_f="10339">27</offsets></xref><offsets xml_i="17182" xml_f="17395" txt_i="10339" txt_f="10552">] It has been reported that after prophylactic administration of 4 mg ondansetron in radical mastoidectomy, nausea, and vomiting occurred at the rate of 33% while they occurred at the rate of 81.5% after placebo.[</offsets><xref rid="ref28" ref-type="bibr"><offsets xml_i="17429" xml_f="17431" txt_i="10552" txt_f="10554">28</offsets></xref><offsets xml_i="17438" xml_f="17447" txt_i="10554" txt_f="10563">] Tramèr </offsets><italic><offsets xml_i="17455" xml_f="17460" txt_i="10563" txt_f="10568">et al</offsets></italic><offsets xml_i="17469" xml_f="17471" txt_i="10568" txt_f="10570">.[</offsets><xref rid="ref29" ref-type="bibr"><offsets xml_i="17505" xml_f="17507" txt_i="10570" txt_f="10572">29</offsets></xref><xref rid="ref30" ref-type="bibr"><offsets xml_i="17548" xml_f="17550" txt_i="10572" txt_f="10574">30</offsets></xref><offsets xml_i="17557" xml_f="17850" txt_i="10574" txt_f="10867">] found that the anti-vomiting efficacy of ondansetron was consistently better than the anti-nausea efficacy. In this study, patients who received ondansetron showed a higher incidence of nausea than those who received midazolam in the first 24 h; however, this difference was not significant.</offsets></p><p><offsets xml_i="17857" xml_f="17928" txt_i="10868" txt_f="10939">Midazolam is a short-acting drug in the benzodiazepine class. Splinter </offsets><italic><offsets xml_i="17936" xml_f="17941" txt_i="10939" txt_f="10944">et al</offsets></italic><offsets xml_i="17950" xml_f="17952" txt_i="10944" txt_f="10946">.[</offsets><xref rid="ref31" ref-type="bibr"><offsets xml_i="17986" xml_f="17988" txt_i="10946" txt_f="10948">31</offsets></xref><offsets xml_i="17995" xml_f="18197" txt_i="10948" txt_f="11150">] observed that administering midazolam 0.05 mg/kg after induction of anesthesia had antiemetic effects that were similar to the same dose of droperidol in children undergoing strabismus surgery. Bauer </offsets><italic><offsets xml_i="18205" xml_f="18210" txt_i="11150" txt_f="11155">et al</offsets></italic><offsets xml_i="18219" xml_f="18221" txt_i="11155" txt_f="11157">.[</offsets><xref rid="ref32" ref-type="bibr"><offsets xml_i="18255" xml_f="18257" txt_i="11157" txt_f="11159">32</offsets></xref><offsets xml_i="18264" xml_f="18422" txt_i="11159" txt_f="11317">] found that preoperative IV midazolam 0.04 mg/kg was an effective way to reduce the frequency of PONV and increased patient satisfaction. Recently, Splinter </offsets><italic><offsets xml_i="18430" xml_f="18435" txt_i="11317" txt_f="11322">et al</offsets></italic><offsets xml_i="18444" xml_f="18446" txt_i="11322" txt_f="11324">.[</offsets><xref rid="ref33" ref-type="bibr"><offsets xml_i="18480" xml_f="18482" txt_i="11324" txt_f="11326">33</offsets></xref><offsets xml_i="18489" xml_f="18707" txt_i="11326" txt_f="11544">] demonstrated that midazolam used in sub-hypnotic dose was as effective as ondansetron in treating PONV without untoward sedative effects. The results of the above studies are comparable with the results of our study.</offsets></p><p><offsets xml_i="18714" xml_f="19028" txt_i="11545" txt_f="11859">Midazolam antiemetic effect is triggered by glycine mimetic inhibitory effect, augmentation of the inhibitory effect of gamma-amino-butyric acid, augmentation of adenosinergic effects, inhibition of dopamine release, and augmentation of adenosine-mediated inhibition of dopamine in the chemoreceptor trigger zone.[</offsets><xref rid="ref33" ref-type="bibr"><offsets xml_i="19062" xml_f="19064" txt_i="11859" txt_f="11861">33</offsets></xref><offsets xml_i="19071" xml_f="19072" txt_i="11861" txt_f="11862">]</offsets></p><p><offsets xml_i="19079" xml_f="19572" txt_i="11863" txt_f="12356">One of the clinical effects of midazolam is sedation. It was probable that the using midazolam prolonged sedation time in the recovery room. Our study showed that midazolam did not prolong PACU and extubation time. It was due to using sub-hypnotic dose midazolam for prevention of PONV. It was presumed from the results of our study that the more efficacy of using midazolam-ondansetron combination in comparison with using each drug singly originates from the synergistic effect of two drugs.</offsets></p><p><offsets xml_i="19579" xml_f="19910" txt_i="12357" txt_f="12688">In conclusion, our study showed that the prophylactic antiemetic effect of the combination of 0.75 mg/kg midazolam with 4 mg ondansetron was superior to using midazolam or ondansetron singly in the first 24 h after operation. Further studies using this combination in the other surgeries with high incidence of PONV is recommended.</offsets></p></sec><sec id="sec1-5"><title><offsets xml_i="19944" xml_f="19966" txt_i="12690" txt_f="12712">AUTHORS’ CONTRIBUTIONS</offsets></title><p><offsets xml_i="19977" xml_f="20182" txt_i="12713" txt_f="12918">MRS has planned the study and finalized it; AH, MC, MN, and MRS did the statistical analysis and prepared the first version of manuscript for publishing. All authors read and approved the final manuscript.</offsets></p><sec id="sec2-1"><title><offsets xml_i="20210" xml_f="20243" txt_i="12919" txt_f="12952">Financial support and sponsorship</offsets></title><p><offsets xml_i="20254" xml_f="20358" txt_i="12953" txt_f="13057">Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="20392" xml_f="20413" txt_i="13059" txt_f="13080">Conflicts of interest</offsets></title><p><offsets xml_i="20424" xml_f="20459" txt_i="13081" txt_f="13116">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank sincerely the support of all the colleagues in Kashani Hospital Medical Center affiliated to Isfahan University of Medical Sciences in Isfahan, Iran. Furthermore, our special thanks go to the patients, who wholeheartedly and actively assisted us to carry out this research. No conflict of interest existed. This prospective randomized observational study was approved by the Ethics Committee of our university, (Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran) and all patients gave written, informed consent.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koivuranta</surname><given-names>MK</given-names></name><name><surname>Läärä</surname><given-names>E</given-names></name><name><surname>Ryhänen</surname><given-names>PT</given-names></name></person-group><article-title>Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomised, double-blind, placebo-controlled trial</article-title><source>Anaesthesia</source><year>1996</year><volume>51</volume><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8669567</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>T</given-names></name><name><surname>Sloan</surname><given-names>F</given-names></name><name><surname>Dear Gde</surname><given-names>L</given-names></name><name><surname>El-Moalem</surname><given-names>HE</given-names></name><name><surname>Lubarsky</surname><given-names>DA</given-names></name></person-group><article-title>How much are patients willing to pay to avoid postoperative nausea and vomiting?</article-title><source>Anesth Analg</source><year>2001</year><volume>92</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">11159239</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>PF</given-names></name><name><surname>Wender</surname><given-names>RH</given-names></name><name><surname>Quon</surname><given-names>R</given-names></name><name><surname>Sloninsky</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting</article-title><source>Anesth Analg</source><year>2001</year><volume>93</volume><fpage>906</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11574355</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frighetto</surname><given-names>L</given-names></name><name><surname>Loewen</surname><given-names>PS</given-names></name><name><surname>Dolman</surname><given-names>J</given-names></name><name><surname>Marra</surname><given-names>CA</given-names></name></person-group><article-title>Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery</article-title><source>Can J Anaesth</source><year>1999</year><volume>46</volume><fpage>536</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10391600</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isik</surname><given-names>B</given-names></name><name><surname>Cekmen</surname><given-names>N</given-names></name><name><surname>Arslan</surname><given-names>M</given-names></name><name><surname>Ozsoylar</surname><given-names>O</given-names></name><name><surname>Kordan</surname><given-names>AZ</given-names></name><name><surname>Akcabay</surname><given-names>M</given-names></name></person-group><article-title>Comparison of the antiemetic effects of ondansetron and dexamethasone on middle ear surgery</article-title><source>Saudi Med J</source><year>2006</year><volume>27</volume><fpage>646</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16680254</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>AS</given-names></name><name><surname>Gan</surname><given-names>TJ</given-names></name></person-group><article-title>Evidence-based management of postoperative nausea and vomiting: A review</article-title><source>Can J Anaesth</source><year>2004</year><volume>51</volume><fpage>326</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15064261</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Greim</surname><given-names>CA</given-names></name><name><surname>Haubitz</surname><given-names>I</given-names></name><name><surname>Grundt</surname><given-names>D</given-names></name><name><surname>Goepfert</surname><given-names>C</given-names></name><name><surname>Sefrin</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>The discriminating power of a risk score for postoperative vomiting in adults undergoing various types of surgery</article-title><source>Acta Anaesthesiol Scand</source><year>1998</year><volume>42</volume><fpage>502</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9605364</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><article-title>American Society of Health System Pharmacists. ASHS Therapeutic guideline on the management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery</article-title><source>Am J Health Syst Pharm</source><year>1999</year><volume>56</volume><fpage>729</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10326616</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Ho</surname><given-names>ST</given-names></name><name><surname>Tzeng</surname><given-names>JI</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name></person-group><article-title>The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting</article-title><source>Anesth Analg</source><year>2000</year><volume>91</volume><fpage>136</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10866900</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McRae</surname><given-names>RG</given-names></name><name><surname>Weissburg</surname><given-names>AJ</given-names></name><name><surname>Chang</surname><given-names>KW</given-names></name></person-group><article-title>Iatrogenic hyponatremia: A cause of death following pediatric tonsillectomy</article-title><source>Int J Pediatr Otorhinolaryngol</source><year>1994</year><volume>30</volume><fpage>227</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">7836036</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gayer</surname><given-names>S</given-names></name><name><surname>Lubarsky</surname><given-names>DA</given-names></name></person-group><article-title>Cost-effective Antiemesis</article-title><source>Int Anesthesiol Clin</source><year>2003</year><volume>41</volume><fpage>145</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">14574219</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramèr</surname><given-names>MR</given-names></name></person-group><article-title>Strategies for postoperative nausea and vomiting</article-title><source>Best Pract Res Clin Anaesthesiol</source><year>2004</year><volume>18</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">15460553</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goksu</surname><given-names>S</given-names></name><name><surname>Kocoglu</surname><given-names>H</given-names></name><name><surname>Bayazit</surname><given-names>YA</given-names></name><name><surname>Yüksek</surname><given-names>S</given-names></name><name><surname>Karci</surname><given-names>Y</given-names></name><name><surname>Kanlikama</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery</article-title><source>Auris Nasus Larynx</source><year>2002</year><volume>29</volume><fpage>253</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12167446</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovac</surname><given-names>AL</given-names></name></person-group><article-title>Prevention and treatment of postoperative nausea and vomiting</article-title><source>Drugs</source><year>2000</year><volume>59</volume><fpage>213</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10730546</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nader</surname><given-names>ND</given-names></name><name><surname>Simpson</surname><given-names>G</given-names></name><name><surname>Reedy</surname><given-names>RL</given-names></name></person-group><article-title>Middle ear pressure changes after nitrous oxide anesthesia and its effect on postoperative nausea and vomiting</article-title><source>Laryngoscope</source><year>2004</year><volume>114</volume><fpage>883</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15126749</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>RJ</given-names></name><name><surname>Inall</surname><given-names>FC</given-names></name></person-group><article-title>The physiology and pharmacology of postoperative nausea and vomiting</article-title><source>Anaesthesia</source><year>1994</year><volume>49 Suppl</volume><fpage>2</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8129158</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safavi</surname><given-names>M</given-names></name><name><surname>Honarmand</surname><given-names>A</given-names></name><name><surname>Negahban</surname><given-names>M</given-names></name><name><surname>Attari</surname><given-names>M</given-names></name></person-group><article-title>Prophylactic effects of intrathecal Meperidine and intravenous Ondansetron on shivering in patients undergoing lower extremity orthopedic surgery under spinal anesthesia</article-title><source>J Res Pharm Pract</source><year>2014</year><volume>3</volume><fpage>94</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25328899</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honarmand</surname><given-names>A</given-names></name><name><surname>Safavi</surname><given-names>M</given-names></name><name><surname>Khalili</surname><given-names>G</given-names></name><name><surname>Mohammadnejad</surname><given-names>F</given-names></name></person-group><article-title>Prophylactic administration of haloperidol plus midazolam reduces postoperative nausea and vomiting better than using each drug alone in patients undergoing middle ear surgery</article-title><source>Saudi J Anaesth</source><year>2012</year><volume>6</volume><fpage>145</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">22754441</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>VK</given-names></name><name><surname>Mathew</surname><given-names>PJ</given-names></name><name><surname>Hegde</surname><given-names>H</given-names></name></person-group><article-title>Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: A randomised, double-blind placebo controlled study</article-title><source>Anaesthesia</source><year>2009</year><volume>64</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">19453311</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apfel</surname><given-names>CC</given-names></name><name><surname>Läärä</surname><given-names>E</given-names></name><name><surname>Koivuranta</surname><given-names>M</given-names></name><name><surname>Greim</surname><given-names>CA</given-names></name><name><surname>Roewer</surname><given-names>N</given-names></name></person-group><article-title>A simplified risk score for predicting postoperative nausea and vomiting: Conclusions from cross-validations between two centers</article-title><source>Anesthesiology</source><year>1999</year><volume>91</volume><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">10485781</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honkavaara</surname><given-names>P</given-names></name></person-group><article-title>Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia</article-title><source>Br J Anaesth</source><year>1996</year><volume>76</volume><fpage>316</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8777119</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>D</given-names></name><name><surname>Kenny</surname><given-names>GN</given-names></name></person-group><article-title>5-HT3 antagonists in postoperative nausea and vomiting</article-title><source>Br J Anaesth</source><year>1992</year><volume>69</volume><issue>7 Suppl 1</issue><fpage>63S</fpage><lpage>8S</lpage><pub-id pub-id-type="pmid">1486016</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naguib</surname><given-names>M</given-names></name><name><surname>el Bakry</surname><given-names>AK</given-names></name><name><surname>Khoshim</surname><given-names>MH</given-names></name><name><surname>Channa</surname><given-names>AB</given-names></name><name><surname>el Gammal</surname><given-names>M</given-names></name><name><surname>el Gammal</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: A randomized, double-blind comparison with placebo</article-title><source>Can J Anaesth</source><year>1996</year><volume>43</volume><fpage>226</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8829860</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbrook</surname><given-names>RA</given-names></name><name><surname>Freiberger</surname><given-names>D</given-names></name><name><surname>Gosnell</surname><given-names>JL</given-names></name><name><surname>Brooks</surname><given-names>DC</given-names></name></person-group><article-title>Prophylactic antiemetic for laparoscopic Cholecystectomy: Ondansetron versus droperidol olus metoclopramide</article-title><source>Anesth Analg</source><year>1996</year><volume>83</volume><fpage>1081</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8895290</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbrook</surname><given-names>RA</given-names></name><name><surname>Gosnell</surname><given-names>JL</given-names></name><name><surname>Freiberger</surname><given-names>D</given-names></name></person-group><article-title>Prophylactic antiemetics for laparoscopic cholecystectomy: A comparison of perphenazine, droperidol plus ondansetron, and droperidol plus metoclopramide</article-title><source>J Clin Anesth</source><year>1998</year><volume>10</volume><fpage>494</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9793814</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>BK</given-names></name><name><surname>Pearman</surname><given-names>MH</given-names></name><name><surname>Kovac</surname><given-names>AL</given-names></name><name><surname>Chelly</surname><given-names>JE</given-names></name><name><surname>Wetchler</surname><given-names>BV</given-names></name><name><surname>McKenzie</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: A randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group</article-title><source>Eur J Anaesthesiol</source><year>2000</year><volume>17</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">10758440</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyermek</surname><given-names>L</given-names></name></person-group><article-title>Pharmacology of serotonin as related to anesthesia</article-title><source>J Clin Anesth</source><year>1996</year><volume>8</volume><fpage>402</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">8832453</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadhasivam</surname><given-names>S</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Kathirvel</surname><given-names>S</given-names></name><name><surname>Kannan</surname><given-names>TR</given-names></name><name><surname>Trikha</surname><given-names>A</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name></person-group><article-title>The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy</article-title><source>Anesth Analg</source><year>1999</year><volume>89</volume><fpage>1340</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10589605</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramèr</surname><given-names>MR</given-names></name><name><surname>Phillips</surname><given-names>C</given-names></name><name><surname>Reynolds</surname><given-names>DJ</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name></person-group><article-title>Cost-effectiveness of ondansetron for postoperative nausea and vomiting</article-title><source>Anaesthesia</source><year>1999</year><volume>54</volume><fpage>226</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10364857</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramèr</surname><given-names>MR</given-names></name><name><surname>Reynolds</surname><given-names>DJ</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name></person-group><article-title>Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials</article-title><source>Anesthesiology</source><year>1997</year><volume>87</volume><fpage>1277</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">9416710</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Splinter</surname><given-names>W</given-names></name><name><surname>Noël</surname><given-names>LP</given-names></name><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Rhine</surname><given-names>E</given-names></name><name><surname>Bonn</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>W</given-names></name></person-group><article-title>Antiemetic prophylaxis for strabismus surgery</article-title><source>Can J Ophthalmol</source><year>1994</year><volume>29</volume><fpage>224</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7859174</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>KP</given-names></name><name><surname>Dom</surname><given-names>PM</given-names></name><name><surname>Ramirez</surname><given-names>AM</given-names></name><name><surname>O’Flaherty</surname><given-names>JE</given-names></name></person-group><article-title>Preoperative intravenous midazolam: Benefits beyond anxiolysis</article-title><source>J Clin Anesth</source><year>2004</year><volume>16</volume><fpage>177</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15217656</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Splinter</surname><given-names>WM</given-names></name><name><surname>MacNeill</surname><given-names>HB</given-names></name><name><surname>Menard</surname><given-names>EA</given-names></name><name><surname>Rhine</surname><given-names>EJ</given-names></name><name><surname>Roberts</surname><given-names>DJ</given-names></name><name><surname>Gould</surname><given-names>MH</given-names></name></person-group><article-title>Midazolam reduces vomiting after tonsillectomy in children</article-title><source>Can J Anaesth</source><year>1995</year><volume>42</volume><fpage>201</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">7743569</pub-id></element-citation></ref></ref-list></back></article>